Skip to Main Content

After a decade of manufacturing problems, a U.S. federal court ordered a unit of Wockhardt, one of the largest makers of generic drugs, to refrain from making allegedly adulterated medicines at a facility in Illinois. However, the U.S. subsidiary, Morton Grove Pharmaceuticals, recently decided to discontinue operations at the site, according to court documents.

The move came after the Department of Justice last week filed a lawsuit alleging that Morton Grove failed to have adequate procedures to prevent cross-contamination of equipment, failed to reject batches that used a contaminated ingredient, and also failed to investigate how the contamination occurred.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment